



**RE-LY<sup>®</sup>**

Study of stroke prevention  
in atrial fibrillation

## Media Invitation

**Dabigatran etexilate:**  
**Challenging the approach to stroke  
prevention in atrial fibrillation**

Monday 30 August 2010; 16.15 – 17:30  
Industry Press Conference Room

Please join us for an exclusive presentation and  
discussion on the latest data from the RE-LY<sup>®</sup> trial  
and the implications for guidelines and daily practice

Food and beverages will be available to media  
attending this session





# RELY®

Study of stroke prevention  
in atrial fibrillation

## AGENDA

- |       |  |       |  |
|-------|--|-------|--|
| 16:15 | <b>Registration</b>  | 16:47 | <b>Preventing stroke in atrial fibrillation:<br/>a year after the landmark RE-LY® Trial</b><br>Dr. Jonas Oldgren, Uppsala University Hospital,<br>Sweden |
| 16:30 | <b>Welcome and Introductions</b><br>John Illman, UK  | 17:12 | <b>Evolving clinical guidelines in atrial fibrillation</b><br>Prof. Gregory Lip, University of Birmingham, UK  |
| 16:32 | <b>Boehringer Ingelheim's commitment to stroke<br/>prevention</b><br>Dr. Jeffrey Friedman, Boehringer Ingelheim,<br>Therapeutic Area Head, Cardiovascular, US    | 17:22 | <b>Questions to the Panel</b><br>Facilitated by John Illman, UK  |
| 16:37 | <b>Understanding atrial fibrillation &amp; the risk of stroke</b><br>Prof. Claus Wallesch, BDH-Clinic Elzach, Clinic<br>for Neurological Rehabilitation, Germany | 17:30 | <b>Close of session</b>  |

### For Non-US Healthcare Media Only

For further information, please contact:

e: [sebastian.wachtarz@boehringer-ingelheim.com](mailto:sebastian.wachtarz@boehringer-ingelheim.com)

t: +49 (6132) 77-3519

e: [luke.willats@ohpr.com](mailto:luke.willats@ohpr.com)

t: +44 (0) 7793 019560

Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation. The marketing authorization for dabigatran etexilate may vary from country to country. In Sweden, dabigatran etexilate (Pradaxa®) is approved for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.